Breaking news

Authors describe mRNA1273-elicited binding and neutralizing antibodies in 33 healthy adults in an ongoing phase 1 trial, 180 days after the second dose of 100 μg (day 209).

Whether or not people who have been infected SARS-CoV-2 should be vaccinated is unclear. This observational cohort study, the authors enrolled 100 health care workers, including 38 with a documented history of SARS-CoV-2 infection.

In this article, the authors report findings in five patients who presented with venous thrombosis and thrombocytopenia 7 to 10 days after receiving the first dose of the ChAdOx1nCoV-19 adenoviral vector vaccine against COVID-19.

In this article, the authors report findings in 23 patients who presented with thrombosis and thrombocytopenia 6 to 24 days after receiving the first dose of the ChAdOx1 nCoV-19 vaccine (AstraZeneca).

In this article the authors assessed the clinical and laboratory features of 11 patients in Germany and Austria in whom thrombosis or thrombocytopenia had developed after vaccination with ChAdOx1 nCov-19.

Many pregnant people in the United States have received mRNA COVID-19 vaccines, but data are limited on their safety in pregnancy. The authors of this study used data from the “v-safe after vaccination health checker” surveillance system, the v-safe pregnancy registry, and the Vaccine Adverse Event Reporting System (VAERS) to characterize the initial safety of mRNA COVID-19 vaccines in pregnant people.

The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length SARS-CoV-2 spike protein in a prefusion-stabilized conformation.

The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study

Impact of the COVID‐19 pandemic on stroke teleconsultations in Germany in the first half of 2020

Impact of the COVID‐19 pandemic and a national lockdown on hospitalisation for stroke and related 30‐day mortality in France: a nationwide observational study

Outcomes and risk factors associated with SARS-CoV-2 infection in a north American registry of patients with multiple sclerosis

Acute transverse myelitis with dysautonomia following SARS-CoV-2 infection: a case report and review of literature

Neurological outcome and quality of life three months after COVID-19: a prospective observational cohort study

Impact of SARS-CoV-2 on reperfusion therapies for acute ischemic stroke in Lombardy, Italy: the STROKOVID network

Brain and lung imaging correlation in patients with COVID-19: could the severity of lung disease reflect the prevalence of acute abnormalities on neuroimaging? a global multicenter observational Study